pyrotinib

Key facts

Mechanism of action

Receptor protein-tyrosine kinase erbB-2 inhibitor

Primary target: Epidermal growth factor receptor

Approval history

1. Fulvestrant combined with Pyrotinib Phase 3 · Sun Yat-sen Memorial · Breast Cancer
2. NJMU-BC01 Phase 2 · First People's Hospital · Breast Cancer
3. Neoadjuvant therapy: TCbHPy Phase 2 · First People's Hospital · Breast Cancer
4. Pyrotinib Phase 2 · First People's Hospital · Breast Cancer
5. pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy Phase 2 · First People's Hospital · HER2-positive Breast Cancer
6. Pyrotinib low dose group Phase 1 · Chinese Academy of · Breast Cancer

1. erlotinib hydrochloride Epidermal growth factor receptor erbB1 inhibitor
2. lapatinib ditosylate Receptor protein-tyrosine kinase erbB-2 inhibitor
3. mobocertinib Antineoplastic and immunomodulating agents (L01)
4. mobocertinib succinate Epidermal growth factor receptor erbB1 inhibitor
5. neratinib maleate Receptor protein-tyrosine kinase erbB-2 inhibitor
6. afatinib dimaleate Epidermal growth factor receptor erbB1 inhibitor

Frequently asked questions